Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Masoli

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Health and Quality of Life Outcomes|October 10, 2020
Validation of subscales of the Severe Asthma Questionnaire (SAQ) using exploratory factor analysis (EFA)Joseph W Lanario, Michael E Hyland, Andrew Menzies-Gow, et al.
Chronic Respiratory Disease|September 27, 2021
Comparison of the sensitivity of patient-reported outcomes for detecting the benefit of biologics in severe asthmaMichael E Hyland, Joseph W Lanario, Andrew Menzies-Gow, et al.
The European Respiratory Journal|February 26, 2021
The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important differenceMatthew Masoli, Joseph W Lanario, Michael E Hyland, et al.
Clinical Therapeutics|August 27, 2019
Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX StudySandhya Khurana, Guy G Brusselle, Elisabeth H Bel, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 3, 2025
Effects of obesity on response to asthma biologic treatment: Longitudinal data from the United Kingdom Severe Asthma RegistrySherif Gonem, Charlene Redmond, John Busby, et al.
BMJ Open Respiratory Research|June 24, 2025
Pre-biologic assessment of adherence in severe asthma and association with biologic continuation: a UK Severe Asthma Registry StudyFreda Yang, Ronald McDowell, John Busby, et al.
ERJ Open Research|April 6, 2023
Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysisJohannes A Kroes, Rafael Alfonso-Cristancho, Aruna T Bansal, et al.
ERJ Open Research|May 18, 2022
The effect of the COVID-19 pandemic on severe asthma care in Europe: will care change for good?Katrien Eger, Dora Paroczai, Alison Bacon, et al.
The European Respiratory Journal|November 7, 2024
Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthmaEkaterina Khaleva, Chris Brightling, Thomas Eiwegger, et al.
The Lancet. Respiratory Medicine|June 24, 2026
Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma RegistryEvangelia Fouka, Aruna T Bansal, Kjell Erik Julius Håkansson, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Health and Quality of Life Outcomes|October 10, 2020
Validation of subscales of the Severe Asthma Questionnaire (SAQ) using exploratory factor analysis (EFA)Joseph W Lanario, Michael E Hyland, Andrew Menzies-Gow, et al.
Chronic Respiratory Disease|September 27, 2021
Comparison of the sensitivity of patient-reported outcomes for detecting the benefit of biologics in severe asthmaMichael E Hyland, Joseph W Lanario, Andrew Menzies-Gow, et al.
The European Respiratory Journal|February 26, 2021
The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important differenceMatthew Masoli, Joseph W Lanario, Michael E Hyland, et al.
Clinical Therapeutics|August 27, 2019
Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX StudySandhya Khurana, Guy G Brusselle, Elisabeth H Bel, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 3, 2025
Effects of obesity on response to asthma biologic treatment: Longitudinal data from the United Kingdom Severe Asthma RegistrySherif Gonem, Charlene Redmond, John Busby, et al.
BMJ Open Respiratory Research|June 24, 2025
Pre-biologic assessment of adherence in severe asthma and association with biologic continuation: a UK Severe Asthma Registry StudyFreda Yang, Ronald McDowell, John Busby, et al.
ERJ Open Research|April 6, 2023
Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysisJohannes A Kroes, Rafael Alfonso-Cristancho, Aruna T Bansal, et al.
ERJ Open Research|May 18, 2022
The effect of the COVID-19 pandemic on severe asthma care in Europe: will care change for good?Katrien Eger, Dora Paroczai, Alison Bacon, et al.
The European Respiratory Journal|November 7, 2024
Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthmaEkaterina Khaleva, Chris Brightling, Thomas Eiwegger, et al.
The Lancet. Respiratory Medicine|June 24, 2026
Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma RegistryEvangelia Fouka, Aruna T Bansal, Kjell Erik Julius Håkansson, et al.
Pageof 4